Arlington Capital Partners has agreed to sell Riverpoint Medical to Novanta for $1.2 billion, marking a significant exit in the medical device sector. The Portland, Oregon-based company specializes in complex implant assemblies and proprietary coatings for medical applications. Doug King leads Riverpoint as CEO.

Riverpoint's portfolio centers on specialized implants and constructs requiring intricate assembly processes, plus innovative IP-protected coatings for both absorbable and non-absorbable implant materials. These proprietary technologies position the company as a niche player in orthopedic and surgical solutions.

The transaction values Riverpoint at approximately $1.2 billion, representing a substantial return for Arlington's investment. Deal completion is targeted for the third quarter of 2026, pending regulatory approvals and customary closing conditions.

This acquisition strengthens Novanta's position in the medical technology space while providing Arlington Capital an opportunity to realize gains from its portfolio company. The sale reflects ongoing consolidation in medical device manufacturing as larger players seek specialized capabilities.